Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

SGLT-2i

  • Home
  • SGLT-2i
Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors
Posted inClinical Updates Diabetes & Endocrinology news

Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors

Posted by MedXY By MedXY 02/28/2026
A large-scale target trial emulation demonstrates that GLP-1RAs significantly reduce heart failure hospitalization risks compared to DPP-4 inhibitors and provide comparable protection to SGLT-2 inhibitors in routine clinical practice.
Read More
  • Severe Lead Poisoning During Pregnancy: Insights from a 19-Year NYC Observational Study
  • Unraveling Fibroblast Diversity in Vaginal Wall Prolapse: Insights from Single-Nucleus Transcriptomics
  • Reclassifying Pediatric NAFLD: Insights from the Steatotic Liver Disease Framework in a Multicenter NASH CRN Study
  • Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen
  • MAD-MT Score: Enhancing Patient Selection for Mechanical Thrombectomy in Distal Vessel Occlusions
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in